Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2011

01-07-2011 | Original Article

PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline

Authors: Jeffrey A. Kolthammer, David J. Corn, Nathan Tenley, Chunying Wu, Haibin Tian, Yanming Wang, Zhenghong Lee

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2011

Login to get access

Abstract

Purpose

Choline-based radiotracers have been studied for PET imaging of hepatocellular carcinoma (HCC). Using an 18F-labeled choline analog, instead of the 11C-labeled native choline, would facilitate its widespread use in the clinic. In this study, PET with 18F-fluoroethylcholine (FEC) and 11C-choline (CHOL) were compared using an animal model of HCC. The effects of fasting on the performance of choline-based tracers were also investigated.

Methods

A woodchuck model of HCC was used to compare the two tracers, which were administered and imaged in sequence during the same imaging session. Dynamic PET images were generated spanning 50 min starting from tracer injection. Time–activity curves and tracer contrast were calculated in liver regions with tracer accumulation, and the contrast at a late time-point with the two tracers, and between fasted and nonfasted states, were compared.

Results

Foci of HCC with increased uptake ranged in size from 1.0 to 1.6 cm, with mean tumor-to-background contrast of 1.3 with FEC and 1.5 with CHOL at 50 min after injection. The tracers show similar patterns of uptake immediately following administration, and both activities plateaued at 10 min after injection. No significant differences in uptake dynamics or final contrast were observed between the fasted and nonfasted states.

Conclusion

PET imaging of HCC is possible with both CHOL and FEC. Fasting was not found to affect accumulation of either tracer. These results encourage further investigation into the clinical utility of FEC for HCC imaging.
Literature
1.
Zeisel SH. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr. 1981;1:95–121.PubMedCrossRef
2.
Kuang Y, Salem N, Tian H, et al. Imaging of lipid synthesis in hepatocellular carcinoma correlated with metabolism study in vivo. J Nucl Med. 2009;50(S2):1577.
3.
Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39(6):990–5.PubMed
4.
Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49(8):1245–8.PubMedCrossRef
5.
Fei B, Wang H, Wu C, Chiu S. Choline PET for monitoring early tumor response to photodynamic therapy. J Nucl Med. 2010;51(1):130–8.PubMedCrossRef
6.
Hara T, Kosaka N, Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry and prostate cancer imaging. J Nucl Med. 2002;43(2):187–99.PubMed
7.
DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61(1):110–7.PubMed
8.
Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010;12(1):98–107.PubMedCrossRef
9.
Coleman R, DeGrado T, Wang S, Baldwin S, Orr M, Reiman R, et al. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging. 2000;3(4):147.PubMedCrossRef
10.
Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology. 2004;127(5):S153–8.PubMedCrossRef
11.
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med. 2008;340(10):745–50.CrossRef
12.
Delbeke D, Patton JA, Martin WH, Sandler MP. Positron imaging in oncology: present and future. In: Freeman LM, editor. Nuclear medicine annual. Philadelphia: Lippincott-Raven; 1998. p. 1–49.
13.
Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36(10):1811–7.PubMed
14.
Balogova S, Bumsel F, Kerrou K, et al. La fluorocholine(18F) a une utilite clinique dans le cancer de la prostate et le carcinome hepatocellulaire... parfois chez le meme malade. Med Nucl. 2010;34(7):378–82.
15.
Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33(11):1285–9.PubMedCrossRef
16.
Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51(11):1699–706PubMedCrossRef
17.
Pascali C, Bogni A, Iwata R, Cambie M, Bombardieri E. [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Comp Radiopharm. 2000;43:195–203.CrossRef
18.
Matej S, Karp JS, Member S, Lewitt RM. Application of the row action maximum likelihood algorithm with spherical basis functions to clinical PET imaging. IEEE Trans Nucl Sci. 2001;48(1):24–30.CrossRef
19.
Salem N, Maclennan GT, Kuang Y, et al. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol. 2007;9(3):135–43.PubMedCrossRef
20.
Devés R, Krupka RM. The binding and translocation steps in transport as related to substrate structure. A study of the choline carrier of erythrocytes. Biochim Biophys Acta. 1979;557(2):469–85.PubMedCrossRef
21.
Clary GL, Tsai CF, Guyunn RW. Substrate specificity of choline kinase. Arch Biochem Biophys. 1987;254(1):214–21.PubMedCrossRef
22.
Kolthammer JA, Tian H, Wu C, et al. In vivo comparison of [18-F]fluorocholine and [11-C]choline for PET imaging of hepatocellular carcinoma. Mol Imaging Biol. 2009;12:Suppl 1.
23.
DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of [18-F]-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42(12):1805–14.PubMed
24.
DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43(1):92–6.PubMed
25.
Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002. p. 47–109.
26.
Kuang Y, Salem N, Tian H, Kolthammer JA, Corn DJ, Wu C, et al. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11C]choline: correlation with in vivo metabolic studies. J Nucl Med. 2011;52:98–106.PubMedCrossRef
Metadata
Title
PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline
Authors
Jeffrey A. Kolthammer
David J. Corn
Nathan Tenley
Chunying Wu
Haibin Tian
Yanming Wang
Zhenghong Lee
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1743-y

Other articles of this Issue 7/2011

European Journal of Nuclear Medicine and Molecular Imaging 7/2011 Go to the issue

Editorial

Time for radiobiology in the nuclear medicine community

Original Article

Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology

Letter to the Editor

Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET

Review Article

Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting

Letter to the Editor

Focus on…: Čerenkov radiation

Original Article

68Ga-DOTATOC PET/CT and somatostatin receptor (sst1–sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax